Trevi Therapeutics, Inc. TRVI Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The source filing: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-110783
For the years ended December 31, 2025 and 2024, the Company generated federal and state net operating losses (“NOLs”) of approximately $38.5 million and $13.1 million, respectively. At December 31, 2025 and 2024, the federal and state net operating loss balances were approximately $238.3 million and $199.8 million, respectively. The federal operating losses generated prior to 2018 will expire in years 2031 through 2037, unless previously utilized. The federal operating losses generated in 2018 or later can be carried forward indefinitely, however will only offset 80% of taxable income in a carryforward year. The state operating losses generated will expire in years 2031 through 2044, unless previously utilized. The Company also generated federal R&D tax credits for the years ended December 31, 2025 and 2024 of approximately $1.2 million and $1.1 million, respectively. At December 31, 2025 and 2024, the federal R&D tax credit carryforwards were approximately $8.5 million and $7.3 million, respectively. These credits will expire in years 2032 through 2055, unless previously utilized. The Company completed a detailed Section 382 analysis, and due to multiple historical ownership changes, the Company’s NOLs as of December 31, 2022, in the amount of $178.4 million and R&D tax credits in the amount of $5.4 million are subject to limitation. If a further ownership change occurs, the Company’s ability to use its tax attributes might be further limited.
Item 16. Form 10-K Summary
FAQ
- What is Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount?
- Trevi Therapeutics, Inc. (TRVI) reported effective income tax rate reconciliation, tax credit, research, amount of $295.25K in Q4 2025.
- How has Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount changed year-over-year?
- Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount increased by 5.8% year-over-year, from $279K to $295.25K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount?
- Over 2 years (2022 to 2025), Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount has grown at a -53.2% compound annual growth rate (CAGR), from $5.4M to $1.18M.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- Represents the monetary value of research and development tax credits applied to reduce the company's income tax expense. These credits are typically granted by governments to incentivize innovation and clinical development activities. This metric is particularly significant for clinical-stage companies as it highlights the utilization of tax incentives to offset operational costs.
Ask your AI about Trevi Therapeutics, Inc.'s effective income tax rate reconciliation, tax credit, research, amount.
Connect your AI assistant and compare it to peers, right in your chat.
